New hope for Alzheimer's disease! First in class drugs recognized by FDA acceleration channel

Source: on October 16, 2017, cognition therapeutics, a clinical neuroscience company focused on developing innovative therapies for Alzheimer's disease and other neurocognitive disorders, announced that the U.S Food and Drug Administration (FDA) has approved the fast track designation for its in-process drug ct1812 for Alzheimer's disease Ct1812 is a first in class oral small molecule drug Recently, phase 1B / 2 clinical study (cog0102) has been completed in patients with mild to moderate Alzheimer's disease This highly permeable compound targets the σ - 2 receptor complex on the synapse of neurons, and can replace the toxic β - amyloid protein (a β) oligomer from the binding site of brain cells, that is, it can inhibit the binding of a β oligomer to the neuron receptor, and promote a β oligomer to clear cerebrospinal fluid Through this mechanism, ct1812 can reduce the toxicity of a β oligomer and allow synaptic regeneration and cognitive performance recovery At present, ct1812 has been shown to prevent memory loss in a variety of Alzheimer's disease models The results of the study cog0102 will be published at the ctad (Alzheimer's clinical trial) conference in Boston on November 2-4, 2017 Ct1812 is the first drug candidate of cognition therapeutics Cognition is a privately-owned biopharmaceutical company with a pipeline to develop small molecule candidate drugs for the treatment of neurocognitive disorders Kenneth I moch, President and CEO of cognition, said: "there are few drugs to treat Alzheimer's disease, and there is no drug that can change the disease But the number of people with Alzheimer's is increasing dramatically, and the burden on families and caregivers, as well as the global health system, is increasing Therefore, we look forward to working with the FDA to commercialize ct1812 through clinical development, and hope that this way can significantly improve the quality of life of people suffering from this devastating disease " The fast track designation is designed to facilitate FDA review of new drugs used to treat serious, life-threatening, and unmet medical needs In the whole process of new drug development, FDA and pharmaceutical companies will communicate in advance and many times This will help to solve the problems of drug approval and early access of patients.